Hims & Hers Health Inc - Ordinary Shares - Class A Quarterly Results and Financial Statement as of Dec, 2024

XNYS: HIMS

Expensive Performer

35.04 6.56 (23.03%)

151.8M XNYS Volume

XNYS 29 Apr, 2025 5:30 PM (EDT)

Partnership

Hims & Hers Health inks a deal with Novo Nordisk to offer weight-loss drug Wegovy at a 63% discount See details

Hims & Hers Health Inc - Ordinary Shares - Class A quarterly, annual results, revenue, profit, P&L, Balance Sheet, Cash Flow, Annual Reports, Margins - 15 Years history